Zevra Therapeutics, Inc. (ZVRA) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-05
(Q2 2026)
— full calendar
Earnings Reports
-
Zephyr (ZVRA) Q1 2026: MyPlypha Reaches 50% Diagnosed U.S. NPC Share, Unlocking Rare Disease Scale
May 07, 2026
-
ZVRA Q4 2025: MyPlypha Drives 52 Annual Enrollments, Expanding Rare Disease Market Penetration
March 10, 2026
-
ZVRA Q3 2025: MyPlypha Drives 40% U.S. Share, European Launch and Diagnosis Initiatives Signal Next Growth Phase
November 06, 2025
-
Zevra (ZVRA) Q2 2025: MyPlypha Drives 26% Sequential Revenue Growth, Expands Rare Disease Reach
August 13, 2025
-
Zevra (ZVRA) Q1 2025: MyPlypha Captures One-Third of Diagnosed NPC Patients, Expanding Rare Disease Franchise
July 07, 2025